The clinical trial program thus far has consisted of schizophrenia and bipolar mania trials involving nearly 3,000 patients.
Schering-Plough acquired asenapine through its combination with Organon BioSciences on November 19, 2007.
About Bipolar Disorder
About schizophrenia
About Schering-Plough
www.schering-plough.comwww.nimh.nih.gov/publicat/bipolar.cfmhttp://www.dbsalliance.org/site/PageServer?pagename=about_statistics_bipolarhttp://www.euro.who.int/document/MNH/emnhqa.pdfhttp://www.nami.org/Template.cfm?Section=bipolar_disorder&template=/ContentManagement/ContentDisplay.cfm&ContentID=44951
5. Perlis RH, Ostacher MJ, Patel JK. Predictors of Recurrence in Bipolar
Disorder: Primary Outcomes from the Systemic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:210-
http://www.who.int/mental_health/management/schizophrenia/en/http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtmlhttp://www.euro.who.int/document/MNH/emnhqa.pdf
CONTACT: Media, Rosemarie Yancosek, +1-908-298-7476, or Monique Mols, +31
412-665440; Investor, Alex Kelly or Robyn Brown, +1-908-298-7436
Web site: http://www.schering-plough.com//
Company News On-Call: http://www.prnewswire.com/comp/777050.html/
